Phase Ia/Ib and Potential Phase IIa Study of the Safety and Pharmacokinetics of NOX66 Both as a Monotherapy and in Combination With Carboplatin in Patients With Refractory Solid Tumours

Trial Profile

Phase Ia/Ib and Potential Phase IIa Study of the Safety and Pharmacokinetics of NOX66 Both as a Monotherapy and in Combination With Carboplatin in Patients With Refractory Solid Tumours

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs Idronoxil (Primary)
  • Indications Advanced breast cancer; Head and neck cancer; Lung cancer; Ovarian cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Noxopharm
  • Most Recent Events

    • 04 Mar 2017 Status changed from not yet recruiting to recruiting.
    • 30 Jan 2017 According to ClinicalTrials.gov record treatment section amended with change in dosing cohorts from three dose cohorts (400 mg, 800 mg and 1200 mg) to two dose cohorts (400 mg and 800 mg) excluding 1200 mg dose cohort.
    • 30 Jan 2017 Planned number of patients changed from 35 to 36.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top